GHRP-2
UnregulatedAlso known as: Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
Growth Hormone SecretagogueLast reviewed: April 28, 2026
A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Considered one of the most potent GHRPs available, producing stronger GH pulses than GHRP-6 but with more appetite stimulation than ipamorelin. Widely used in anti-aging and performance contexts.
Mechanism of Action
Binds to the growth hormone secretagogue receptor (GHS-R1a / ghrelin receptor) in the anterior pituitary, triggering GH release. Also stimulates appetite through hypothalamic ghrelin pathways. Produces a robust GH pulse that synergizes with GHRH analogs like CJC-1295 or sermorelin.
Common Uses
- Growth hormone optimization
- Muscle growth and recovery
- Anti-aging protocols
- Improved sleep quality
- Fat loss (via elevated GH)
Known Risks
- Increased appetite and hunger
- Water retention
- Elevated cortisol and prolactin (dose-dependent)
- Tingling or numbness at injection site
- Potential blood sugar effects
Regulatory Status
Not FDA-approved. Available as a research chemical. Pralmorelin (the INN name) has been studied clinically in Japan for GH deficiency diagnosis but has no approved therapeutic indication in the US.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–300 mcg
Frequency
2–3 times daily (before meals or at bedtime)
Cycle Length
8–12 weeks on, 4 weeks off
Best combined with a GHRH analog (CJC-1295 or sermorelin) for synergistic GH release. Take on an empty stomach — fats and carbs blunt the GH response. Bedtime dose aligns with natural GH pulse.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.